CytoMed Therapeutics (GDTC) Fundamentals 2026 — Revenue Analysis | SniperIQ
CytoMed Therapeutics (GDTC) is a SG-listed Healthcare company in Biotechnology with a market capitalization of
19,201 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CytoMed Therapeutics's market cap?
CytoMed Therapeutics (GDTC) has a market capitalization of approximately
What is CytoMed Therapeutics's P/E ratio?
CytoMed Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CytoMed Therapeutics?
CytoMed Therapeutics runs a net profit margin of -754.7%, a gross margin of -20.5%, and an operating margin of -672.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CytoMed Therapeutics generate?
CytoMed Therapeutics reported revenue of S
Does CytoMed Therapeutics pay a dividend?
CytoMed Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CytoMed Therapeutics financially healthy?
CytoMed Therapeutics carries a debt-to-equity ratio of 0.07x and a current ratio of 5.17x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CytoMed Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CytoMed Therapeutics (GDTC) the key facts are: market cap
19,201, 52-week range 0.68-3.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.Track CytoMed Therapeutics's full fundamentals live
Get CytoMed Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.